France Indapamide Market Trends, Research Report, Growth, Opportunities, Forecast 2022-2028

France indapamide market is estimated to grow significantly at a CAGR of around 3.5% during the forecast period. France indapamide market is being primarily driven by the increasing incidence of stroke and the rising hypertension cases in the country. As per the UN (United Nation), in 2019, there were 13.3 million people aged 65 years or over, which is 20.4% of the total population. Nearly 24.1% of the population is expected to be aged 65 years or over by 2030, which will be nearly 16.1 million people. Moreover, it is estimated that a 40.0% increase in stroke incidence will be witnessed during 2015 and 2030 and a 30.0% increase in prevalence, and 51% increment in mortality Owing to this significant rise in the aging population, a significant demand for the treatment of strokes is expected to arise in the upcoming period that further encourages the demand for indapamide in the country.

A full report of France Indapamide Market is available at: https://www.omrglobal.com/industry-reports/france-indapamide-market

France indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/france-indapamide-market

The companies which are contributing to the growth of the France indapamide market include Merck KGaA, Sanofi S.A., Mylan N.V., Laboratori Baldacci S.p.A., Sandoz International GmbH, Bioindustria L.I.M. S.p.A. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.

France Indapamide Market- Segmentation

By Product

  • 25 MG
  • 5 MG

By Application

  • High Blood Pressure
  • Heart Failure
  • Others